Dr. Eric Wittchow

• Develop R&D roadmap of in-house vs. outsourced products which includes production capabilities in cooperation with other departments eg. marketing and sales • Coordinate project activities beginning with supply of raw material, processing, material analysis, implant production, approval and clinical application (FIM studies) • Maintain knowledge of ISO, RA regulations (MDR, FDA, other) and QM system impact on design, project work and documentation (DHF, TF, DIDOV, V&V, FMEA)

• Directed day-to-day preclinical and translational research services • Oversaw design, execution and analysis for various research facilities and educational activities at CVPath Institute • Coordinate outsourced preclinical studies, histopathological processing as well as final reporting and publications • Streamlined working process of the institution to further its goal of pre-eminence in the field of cardiovascular research

• Set up of preclinical study group • Managed all scientific, organisational and disciplinary aspects of preclinical studies group • Provided independent analysis, evaluation, interpretation and presentation of preclinical results • Developed and customized special analysis methods to characterize bioresorbable and permanent vascular implants (X-ray, Faxitron, µ-CT, IVUS, OCT, degradation analysis)

• Conducted phase-IV clinical studies for immunosuppresiva • Consulted and supported sales force in medical questions • Collected information regarding competitor strategies and therapy optimization programs

• Established premarketing activities and introduced dual therapy for hepatitis B+C therapy • Built network of clinical specialists and key opinion leaders (KOL) • Initiated phase-IV clinical studies, monitored phase-III clinical studies • Raised market share of Intron A (Interferon) from 47% (1998) to 73% (2001)

• Products for paediatry, surgery and oncology

Metallorganische Chemie, Polymerchemie, Pharmazie

Metallorganische Chemie